Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Obesity–PSA relationship: a new formula

Prostate Cancer and Prostatic Diseases volume 13, pages 186–190 (2010)Cite this article

Abstract

To clinically apply the inverse PSA–body mass index (BMI) correlation and enhance PSA sensitivity in obese cases, a new formula is warranted. An innovated BMI–PSA equation is designed. PSA–BMI adjusted formula (named Hekal's equation): measured total PSA (ng ml−1) multiplied by age (years) and divided by BMI of the patient. The formula is applied over a randomly chosen 1000 cases of different PSA, BMI, age and trans-rectal ultrasound biopsy results, the yield of new PSA is correlated with pathology and age-specific PSA adjustment values. Among the 988 cases with complete data, obesity (BMI: 30–35 kg m−2) in 236 cases (23.8%) and 79 cases (7.9%) have BMI>35 kg m−2. Mean PSA was 5.8 ng ml−1 (s.d.±8.4 ng ml−1). Cases stratified based on their age (every 10 years). The new equation was applied. Obesity is detected in 33.5 and 43.6% of fifth and sixth decade of life respectively (P=0.02), with low measured PSA values (2.1, 3.8 ng ml−1, respectively). By such PSA measurement biopsy may be omitted, missing 53.3% of malignant cases. In contrast, PSA adjusted were 4 and 9.3 ng ml−1 within the same group of patients. With such values, the decision of a biopsy could not be missed for the targeted groups. Specificity and sensitivity of adjusted PSA values at cutoff point 4 ng ml−1 was 41.7 and 70%, respectively. Based on our results, the new PSA–BMI adjusted formula is reproducible, easy applied formula. With such a formula the higher sensitivity of PSA in obese patients could be achieved. The misleading low PSA in obese cases in the fifth and sixth decade will be corrected.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Gray MA, Delahunt B, Fowles JR, Weinstein P, Cookes RR, Nacey JN . Demographic and clinical factors as determinants of serum levels of prostate specific antigen and its derivatives. Anticancer Res 2004; 24: 2069–2072.

    PubMed  Google Scholar 

  2. Ochiai A, Fritsche HA, Babaian RJ . Influence of anthropometric measurements, age, and prostate volume on prostate-specific antigen levels in men with a low risk of prostate cancer. Urology 2005; 66: 819–823.

    Article  PubMed  Google Scholar 

  3. Kristal AR, Chi C, Tangen CM, Goodman PJ, Etzioni R, Thompson IM . Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increase. Cancer 2006; 106: 320–328.

    Article  PubMed  Google Scholar 

  4. Freedland SJ, Wen J, Wuerstle M, Shah A, Lai D, Moalej B et al. Obesity is a significant risk factor for prostate cancer at the time of biopsy. Urology 2008; 72: 1102–1105.

    Article  PubMed  Google Scholar 

  5. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993; 270: 860–864.

    Article  CAS  PubMed  Google Scholar 

  6. National Heart Lung and Blood Institute. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults—the evidence report. Obes Res 1998; 6 (Suppl 2): 51S–210S.

    Google Scholar 

  7. Ross LE, Coates RJ, Breen N, Uhler RJ, Potosky AL, Blackman D . Prostate specific antigen test use reported in the 2000 National Health Interview Survey. Prev Med 2004; 38: 732–744.

    Article  PubMed  Google Scholar 

  8. Barqawi AB, Golden BK, O’Donnell C, Brawer MK, Crawford ED . Observed effect of age and body mass index on total and complexed PSA: analysis from a national screening program. Urology 2005; 65: 708–712.

    Article  PubMed  Google Scholar 

  9. Baillargeon J, Pollock BH, Kristal AR, Bradshaw P, Hernandez J, Basler J et al. The association of body mass index and prostate-specific antigen in a population-based study. Cancer 2005; 103: 1092–1095.

    Article  PubMed  Google Scholar 

  10. Rodriguez C, Patel AV, Calle EE, Jacobs EJ, Chao A, Thun MJ . Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol Biomarkers Prev 2001; 10: 345–353.

    CAS  PubMed  Google Scholar 

  11. Vollmer RT, Humphrey PA . Tumor volume in prostate cancer and serum prostate-specific antigen. Analysis from a kinetic viewpoint. Am J Clin Pathol 2003; 119: 80–89.

    Article  PubMed  Google Scholar 

  12. Bañez LL, Hamilton RJ, Partin AW, Vollmer RT, Sun L, Rodriguez C et al. Obesity—related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA 2007; 298: 2275–2280.

    Article  PubMed  Google Scholar 

  13. Moul JW . Words of wisdom. Re: obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. Eur Urol 2008; 54: 232–233.

    Article  PubMed  Google Scholar 

  14. Buschemeyer III WC, Freedland SJ . Obesity and prostate cancer: epidemiology and clinical implications. Eur Urol 2007; 52: 331–343.

    Article  PubMed  Google Scholar 

  15. Kim YJ, Han BK, Hong SK, Byun SS, Kim WJ, Lee SE . Body mass index influences prostate-specific antigen in men younger than 60 years of age. Int J Urol 2007; 14: 1009–1012.

    Article  PubMed  Google Scholar 

  16. Hekal IA . The patients less than 50 years: is there a need to lower the PSA cutoff point? Prostate Cancer Prostatic Dis 2009; 12: 148–151.

    Article  CAS  PubMed  Google Scholar 

  17. Dahle SE, Chokkalingam AP, Gao Y-T, Deng J, Stanczyk FZ, Hsing AW . Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol 2002; 168: 599–604.

    Article  CAS  PubMed  Google Scholar 

  18. Hammarsten J, Hogstedt B . Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 2001; 39: 151–158.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Urology Department, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt

    I A Hekal & E I Ibrahiem

Authors
  1. I A Hekal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E I Ibrahiem
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to I A Hekal.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Appendices

Appendix A

Appendix B

Abbreviations: ng/ml, nanogram per milliliter; BMI, body mass index.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hekal, I., Ibrahiem, E. Obesity–PSA relationship: a new formula. Prostate Cancer Prostatic Dis 13, 186–190 (2010). https://doi.org/10.1038/pcan.2009.53

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/pcan.2009.53

Keywords

This article is cited by

Search

Advanced search

Quick links